Lilly pauses India obesity awareness campaign after regulator warning

Eli Lilly has paused its "We Know Now" obesity awareness campaign in India after the country's drug regulator warned that the effort could violate rules against advertising prescription medicines to consumers, even indirectly, according to a letter seen by Reuters ^[1].

The campaign launched in the middle of 2025, a few months after Lilly introduced its GLP-1 drug Mounjaro for obesity and diabetes in India ^[1]. It used newspaper ads, social media posts, billboards, collaborations with Bollywood celebrities and posters in some residential communities. Lilly's corporate logo appeared on the messages, but Mounjaro was not named ^[1].

In a 16-page letter dated April 10 to the Drugs Controller General of India, Lilly said it had halted the campaign "out of an abundance of regulatory caution" after a March advisory from the regulator ^[1].

That advisory said product advertisements, including surrogate promotions that may indirectly lead consumers to a medicine, are banned across media platforms, and that campaigns or influencer engagement creating brand recall or product visibility would be treated as violations ^[1]. In a separate March notice to Lilly, the regulator said the campaign had coincided with Mounjaro's India launch and could potentially indirectly promote the drug to consumers, according to two people familiar with the matter ^[1].

The regulator also asked Lilly to respond on whether it had reviewed the campaign materials for compliance and what steps it had taken to follow the rules ^[1]. Drugs Controller General of India Rajeev Raghuvanshi did not respond to a request for comment ^[1].

Lilly told the regulator that the guidance created "significant regulatory uncertainty" and appeared to restrict even non-branded, doctor-led campaigns, while the same advisory said the company could run public awareness initiatives and work with medical associations to promote safe medicine use. Lilly called the two positions "irreconcilable" and asked whether physician-led discussions about diseases, without naming specific medicines, fall within the restrictions ^[1]. The company said the pause had "the unintended consequence of silencing a scientifically sound, physician-led public health campaign that was actively serving the interests of patients and the healthcare community" ^[1].

India's Central Drugs Standard Control Organization published its March notice clarifying the ban on direct and indirect prescription medicine marketing in response to alleged promotional activity, and named disease awareness, influencer engagement and corporate campaigns among activities that could break the rules if they drive brand recall or product visibility, Fierce Pharma reported ^[2]. Lilly said its disease-state education focuses on helping the public understand chronic diseases such as obesity and Type 2 diabetes and does not promote any specific medicine, a spokesperson said ^[2]. Videos from the campaign, some featuring Indian celebrities, have been viewed millions of times ^[2].

In a separate case, French authorities fined Lilly over a disease awareness campaign, on the view that although the company did not name its medicines, the campaign tended to encourage the general public to use Mounjaro regardless of weight and body mass index, according to Fierce Pharma ^[2].

India has more than 1.4 billion people and rising rates of overweight and obesity. A government survey from 2019 to 2021 found about 24% of women aged 15-49 and nearly 23% of men aged 15-54 were overweight or obese, up from 20.6% of women and about 19% of men in 2015-2016 ^[1]. Mounjaro became India's top-selling drug in October 2025, ahead of Novo Nordisk's Wegovy, which faces competition from cheaper local generics ^[1]. The Indian obesity market is expected to reach 80 billion rupees ($839.37 million) annually by 2030, from 17.34 billion rupees currently, according to the research firm Pharmarack ^[1].

Why it matters for patients

Direct-to-consumer advertising of prescription medicines is common in the United States, but India prohibits it, and this episode shows how closely regulators are examining campaigns that talk about obesity without naming a product ^[1][2]. The debate is not about whether obesity is a chronic disease, but about when education starts functioning as product promotion. For people in the US taking or considering GLP-1 drugs, the practical effect is indirect: no change to US availability, approval or labeling has been reported, and the pause applies to a campaign in India. What it does illustrate is that the same kind of unbranded messaging that US patients see on billboards, television and social media is being tested elsewhere, and that regulators in at least two countries have concluded such campaigns can steer the public toward a specific medicine ^[2]. Patients who want to judge a message for themselves can note whether a campaign names a drug, carries only a corporate logo, or asks viewers to consult a doctor ^[1][2].

What happens next

Lilly has asked India's regulator for clarity on whether physician-led discussions of disease, without reference to specific medicines, are permitted, and it has not said when or whether it will restart the campaign ^[1]. No timeline for a regulatory response has been reported, and it is not yet known whether Novo Nordisk received a similar advisory; Novo did not immediately respond to a request for comment ^[1]. The outcome of the French case beyond the fine has not been disclosed ^[2].